Galapagos' BioFocus division will discover and validate targets for undisclosed CNS disorders for Astellas

Galapagos N.V.

Belgium / Small-Cap Biopharma (<$1 billion)

Other

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Astellas Pharma Inc.

Japan / Mid-Cap Biopharma ($1-$50 billion)

Other

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced